ArticleeLife2021

Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical.

Elisabeth Gludovacz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.